Factors Examined for Time to First Rx for Biologic DMARD in RA
Longer time to receipt more likely with older age, male sex, greater distance to nearest rheumatologist.
Diagnosis & Disease Information
Avsola, a Biosimilar to Remicade, Gets FDA Approval
The FDA has approved Avsola (infliximab-axxq; Amgen), a biosimilar to Remicade (infliximab; Janssen Biotech).
RediTrex Approved for RA, pJIA, Psoriasis Treatment
The FDA has approved RediTrex (methotrexate injection; Cumberland) for the management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis, who are intolerant of or had an inadequate response to first-line therapy.
Biosimilar Abrilada Gets FDA Approval
The Food and Drug Administration (FDA) has approved Abrilada (adalimumab-afzb; Pfizer), a biosimilar to Humira (adalimumab; AbbVie).
Risk for Birth Defects Not Increased With Adalimumab
Risk for preterm delivery higher in women with RA, Crohn disease regardless of adalimumab exposure.
Rinvoq Meets Primary and Key Secondary Endpoints in Psoriatic Arthritis Trial
AbbVie announced positive topline data from the phase 3 SELECT-PsA 2 trial of upadacitinib (Rinvoq) in patients with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response to ≥1 biologic disease modifying anti-rheumatic drugs (bDMARDs).
Week 52 Data Show Persistent Efficacy With Filgotinib in RA Trial
Filgotinib is an investigational, oral selective JAK1 inhibitor.
Combo Tx May Improve Disease Control for Some in Early RA
Improved disease control, remission, functional capacity for TNF or non-TNF plus methotrexate
Rinvoq Approved for Moderate to Severe Rheumatoid Arthritis
The approval was based on data from five phase 3 trials (the SELECT program) involving approximately 4400 patients with moderate to severe RA, including those who failed or were intolerant to biologic disease-modifying antirheumatic drugs.
Boxed Warning Added to Tofacitinib Prescribing Information
The Food and Drug Administration (FDA) has approved changes to the prescribing information for tofacitinib to include new warnings, including a Boxed Warning, regarding an increased risk of blood clots and death associated with the 10mg twice daily regimen. The update comes after a review of data from an ongoing safety clinical trial of tofacitinib…
